<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625000</url>
  </required_header>
  <id_info>
    <org_study_id>A002-A4</org_study_id>
    <nct_id>NCT01625000</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MP-214 in Patients With Schizophrenia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214&#xD;
      relative to placebo in patients with acute exacerbation of schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>MP-214 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MP-214 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MP-214 9mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-214 3mg</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
    <arm_group_label>MP-214 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-214 6mg</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
    <arm_group_label>MP-214 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-214 9mg</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
    <arm_group_label>MP-214 9mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone 4mg</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
    <arm_group_label>Risperidone 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the patient before the initiation of any&#xD;
             study-specific procedures&#xD;
&#xD;
          -  Patients diagnosed with schizophrenia according to the diagnostic criteria of the&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision&#xD;
             (DSM-IV-TR) criteria for schizophrenia&#xD;
&#xD;
          -  Patients with normal physical examination, laboratory, vital signs, and/or&#xD;
             electrocardiogram (ECG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform&#xD;
             disorder, other psychotic disorders other than schizophrenia, or bipolar I or II&#xD;
             disorder&#xD;
&#xD;
        The information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <results_first_submitted>January 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2021</results_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Acute Schizophrenia</keyword>
  <keyword>Mental Disorder</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Dopamine Agents</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four subjects withdrew from the study before the start of the study medication after being assigned to the treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MP-214 3mg</title>
          <description>MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="P2">
          <title>MP-214 6mg</title>
          <description>MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="P3">
          <title>MP-214 9mg</title>
          <description>MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="P4">
          <title>Risperidone 4mg</title>
          <description>Risperidone 4mg: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event (including Death)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP-214 3mg</title>
          <description>MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="B2">
          <title>MP-214 6mg</title>
          <description>MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="B3">
          <title>MP-214 9mg</title>
          <description>MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="B4">
          <title>Risperidone 4mg</title>
          <description>Risperidone 4mg: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="126"/>
            <count group_id="B6" value="508"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="10.6"/>
                    <measurement group_id="B2" value="40.2" spread="11.4"/>
                    <measurement group_id="B3" value="43.0" spread="9.7"/>
                    <measurement group_id="B4" value="39.5" spread="10.2"/>
                    <measurement group_id="B5" value="40.1" spread="11.1"/>
                    <measurement group_id="B6" value="40.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
        <description>PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>For OC (Observed Case) analysis, the Missing Values were Not included.</population>
        <group_list>
          <group group_id="O1">
            <title>MP-214 3mg</title>
            <description>MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O2">
            <title>MP-214 6mg</title>
            <description>MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>MP-214 9mg</title>
            <description>MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O4">
            <title>Risperidone 4mg</title>
            <description>Risperidone 4mg: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
          <description>PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.</description>
          <population>For OC (Observed Case) analysis, the Missing Values were Not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="2.0"/>
                    <measurement group_id="O2" value="-13.8" spread="2.0"/>
                    <measurement group_id="O3" value="-14.0" spread="2.9"/>
                    <measurement group_id="O4" value="-20.2" spread="3.0"/>
                    <measurement group_id="O5" value="-9.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6</title>
        <description>CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>For OC (Observed Case) analysis, the Missing Values were Not included.</population>
        <group_list>
          <group group_id="O1">
            <title>MP-214 3mg</title>
            <description>MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O2">
            <title>MP-214 6mg</title>
            <description>MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>MP-214 9mg</title>
            <description>MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
          </group>
          <group group_id="O4">
            <title>Risperidone 4mg</title>
            <description>Risperidone 4mg: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6</title>
          <description>CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).</description>
          <population>For OC (Observed Case) analysis, the Missing Values were Not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.1"/>
                    <measurement group_id="O2" value="-0.8" spread="0.1"/>
                    <measurement group_id="O3" value="-0.7" spread="0.2"/>
                    <measurement group_id="O4" value="-1.2" spread="0.2"/>
                    <measurement group_id="O5" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP-214 3mg</title>
          <description>MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="E2">
          <title>MP-214 6mg</title>
          <description>MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="E3">
          <title>MP-214 9mg</title>
          <description>MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.</description>
        </group>
        <group group_id="E4">
          <title>Risperidone 4mg</title>
          <description>Risperidone 4mg: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection masked</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

